Study

Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors

2021 · primary-comparison · peer reviewed: yes · record 34376232 · PubMed

3 findings kept from this study. Each is one sentence comparing an animal with a human, extracted from the full text, checked against the located page, and adjudicated against the review's definition of an animal-versus-human comparison.

The NK cell activation signature was significantly higher in anti-CTLA-4 responsive human tumors than non-responsive tumors.

Concordant · level C · mouse · oncology · 1e-15

“In pre-treatment biopsies, the NK cell activation signature was significantly higher in anti-CTLA-4 responsive tumors than non-responsive tumors (p < 1 × 10-15, Additional file 1: Fig. S2A).”
page 10

The NK cell activation signature had a moderate ability to classify anti-CTLA-4 response in humans.

Concordant · level C · mouse · oncology · 0.748 auc

“Using receiver operating characteristic curve (ROC) analysis, we found that the NK cell activation signature had a moderate ability to classify anti-CTLA-4 response (Fig. 4C, AUC = 0.748), suggesting that the NK activation signature has the potential utility to predict responsiveness to anti-CTLA-4 from pre-treatment tumor biopsies.”
page 11

The NK cell activation signature was significantly enriched in human tumors responsive to combination anti-CTLA-4 and anti-PD-1.

Concordant · level C · mouse · oncology · 0.05

“In contrast, the NK cell activation signature was significantly enriched in tumors responsive to combination anti-CTLA-4 and anti-PD-1 taken before (Fig. 4A, p < 0.05) and during (Fig. 4B, p < 0.01) treatment.”
page 10